Sign Out
Avoid using salmeterol as sole agent for asthma control. Patients should be instructed to stop salmeterol when they have breakthrough asthma symptoms of acute asthma exacerbation and to shift to short acting selective B2 agonist. Avoid use during pregnancy.
Increasing use of short-acting bronchodilators to relieve symptoms indicates deterioration of control and patients should be reviewed by a physician. Sudden and progressive deterioration in control of asthma is potentially life-threatening and the patient should be reviewed by a physician.
Treatment with salmeterol + fluticasone propionate should not be stopped abruptly in patients with asthma due to risk of exacerbation, therapy should be titrated-down under physician supervision. For patients with Chronic Obstructive Pulmonary Disease (COPD), cessation of therapy may be associated with symptomatic decompensation and should be supervised by a physician.
Effects on Ability to drive and Use Machines: There have been no specific studies of the effects of Salmeterol + Fluticasone Propionate on the above activities, but the pharmacology of both drugs does not indicate any effect.
